Skip to content

Study · In vitro (cell-free) · rat · 1988

3 results

Characterization of peptidylglycine alpha-amidating activities in rat pituitary, brain and small intestine using glycine-extended C-terminal analogues of vasoactive intestinal polypeptide as substrate.

Noguchi M, Takahashi K, Okamoto H

The Tohoku journal of experimental medicine1 Oct 1988Cited by 10 (Europe PMC)

PMID3238697 (opens in a new tab)DOI10.1620/tjem.156.191 (opens in a new tab)PepBankPUB-03238697
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Activity measurement

    VIP itself did not inhibit the alpha-amidating activities from rat pituitary, brain and small intestine.

    In plain wordsIn lab tests, VIP itself did not block the rat tissue enzymes that amidate peptides.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeInhibition of alpha-amidating activity by VIP
    Study

    ratn: not reported in source

    Enzyme activities from pituitary, brain and small intestine
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but VIP was not, indicating that the alpha-amidating enzymes from these tissues in common have a recognition site for the C-terminal glycine of the glycine-extended precursor regardless of the length and nature of the sequence.
    1 context sentence
    Summary · context
    Peptidylglycine alpha-amidating activities from rat pituitary, brain and small intestine were compared, utilizing C-terminal analogues of vasoactive intestinal polypeptide (VIP), D-Tyr-Leu-Asn-Gly and D-Tyr-Asn-Gly, and C-terminal analogue of alpha-MSH, D-Tyr-Val-Gly.

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cell-free)Activity measurement

    In rat pituitary, brain and small intestine, enzyme activities converted glycine-extended C-terminal VIP analogues to the alpha-amidated peptides.

    In plain wordsIn lab tests, rat tissue enzymes converted glycine-extended pieces of VIP into the amidated form.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableAlpha-amidation of glycine-extended VIP analogues by tissue enzymes
    Study

    ratn: not reported in source

    Enzyme activities from pituitary, brain and small intestine
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The three tissues had enzymic activities capable of converting the glycine-extended peptides to the corresponding alpha-amidated ones.
    1 context sentence
    Summary · context
    Peptidylglycine alpha-amidating activities from rat pituitary, brain and small intestine were compared, utilizing C-terminal analogues of vasoactive intestinal polypeptide (VIP), D-Tyr-Leu-Asn-Gly and D-Tyr-Asn-Gly, and C-terminal analogue of alpha-MSH, D-Tyr-Val-Gly.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cell-free)Activity measurement

    Desamide VIP-Gly was a potent inhibitor of the alpha-amidating activities from rat tissues.

    In plain wordsIn lab tests, a VIP-derived compound strongly blocked rat tissue enzymes that amidate peptides.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseInhibition of alpha-amidating activity by desamide VIP-Gly
    Study

    ratn: not reported in source

    Enzyme activities from pituitary, brain and small intestine
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Desamide VIP-Gly was proved to be a potent inhibitor of the alpha-amidating activities from the tissues
    1 context sentence
    Summary · context
    Peptidylglycine alpha-amidating activities from rat pituitary, brain and small intestine were compared, utilizing C-terminal analogues of vasoactive intestinal polypeptide (VIP), D-Tyr-Leu-Asn-Gly and D-Tyr-Asn-Gly, and C-terminal analogue of alpha-MSH, D-Tyr-Val-Gly.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.